Abstract
Background: The description of polymorphisms in many of the key immunoregulatory molecules involved in the rejection process has offered a possible explanation for the individual variation in susceptibility to rejection and differences in allograft survival independent of the many known contributory factors. The aim of this work is to study the impact of IL-10 cytokine gene polymorphism on renal transplant clinical course and outcome. Methods: This work studied 50 transplant recipients maintained on sirolimus based immunosuppression for IL-10 cytokine gene polymorphisms. After transplantation patients were divided into two groups. Group (A) patients (12 patients) received sirolimus, tacrolimus and steroid, while Group (B) patients (38 patients) received sirolimus, mycophenolate mofetil and steroid. Results were correlated with acute and chronic rejection episodes as well as graft and patient outcome. Results: In our study, we found no impact of IL-10 on incidence and degree of acute rejection episodes, incidence of chronic allograft nephropathy, pathological changes in protocol biopsies, graft function and graft and patient survivals. Conclusion: From this work, we can conclude that the potential impact of IL-10 cytokine gene polymorphisms on renal transplant clinical course and outcome have shown no influence, and probably other genes rather than IL-10 could be involved as key molecules for graft function.
Highlights
The increasing success at preventing acute renal allograft rejection has resulted in rejection rates of less than 20% and one-year graft survivals of more than 90%.This success rate has led to focus on the improvement in long-term allograft survival, and the adjustment of immunosuppression to the individual need
A possible explanation for the individual variation in rejection susceptibility and differences in allograft survival has been offered by the polymorphisms description of immunoregulatory molecules involved in the rejection process
The explanation was that IL-10 may enhance antibody responses against the graft as reported by Genetic variations including single nucleotide poly- Merville and co-workers in 1995 [15] and low IL-10 morphisms (SNPs), dinucleotide repeats and micro- responses can be used to predict a low risk for acute satellites have been identified in a number of genes graft rejection [16]
Summary
The increasing success at preventing acute renal allograft rejection has resulted in rejection rates of less than 20% and one-year graft survivals of more than 90%.This success rate has led to focus on the improvement in long-term allograft survival, and the adjustment of immunosuppression to the individual need. A possible explanation for the individual variation in rejection susceptibility and differences in allograft survival has been offered by the polymorphisms description of immunoregulatory molecules involved in the rejection process. The description of polymorphisms in many of the key immunoregulatory molecules involved in the rejection process has offered a possible explanation for the individual variation in susceptibility to rejection and differences in allograft survival independent of the many known contributory factors. Results: In our study, we found no impact of IL-10 on incidence and degree of acute rejection episodes, incidence of chronic allograft nephropathy, pathological changes in protocol biopsies, graft function and graft and patient survivals. Conclusion: From this work, we can conclude that the potential impact of IL-10 cytokine gene polymorphisms on renal transplant clinical course and outcome have shown no influence, and probably other genes rather than IL-10 could be involved as key molecules for graft function
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
